Chapel Hill

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Amyloidosis2 trials
• Acute myeloid leukaemia1 trial
• Childhood cancers1 trial
• Myasthenia gravis1 trial
• Neuromyelitis optica (NMOSD)1 trial
• Sarcoidosis1 trial

Phase

• Phase 33 trials
• Phase 2/31 trial

Status

• Recruiting4 trials
• Completed1 trial
• Not yet recruiting1 trial

Lead sponsor

• Alexion Pharmaceuticals, Inc.2 trials
• Alnylam Pharmaceuticals2 trials
• Priovant Therapeutics, Inc.1 trial
• Syndax Pharmaceuticals1 trial

Running trials

• Recruiting

  TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

  NCT07223203· Phase 3· Alnylam Pharmaceuticals· Source

• Recruiting

  Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

  NCT07211958· Phase 3· Syndax Pharmaceuticals· Source

  Contact: Syndax Pharmaceuticals

• Recruiting

  A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis

  NCT06978725· Phase 2/3· Priovant Therapeutics, Inc.· Source

  Contact: Clinical Trial Administrator

• Recruiting

  Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies

  NCT05966467· Alexion Pharmaceuticals, Inc.· Source

  Contact: Irena Dujmovic-Basuroski

• Recruiting

  Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

  NCT04202341· Alexion Pharmaceuticals, Inc.· Source

  Contact: Alexion Pharmaceuticals, Inc. (Sponsor)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukaemia1 recruiting
• Amyloidosis1 recruiting
• Childhood cancers1 recruiting
• Myasthenia gravis1 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Sarcoidosis1 recruiting

Closed trials

• Completed

  HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

  NCT03759379· Phase 3· Alnylam Pharmaceuticals· Source